Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NVO 
Novo Nordisk A/S (NVO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/14/2025: NVO (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $86.98
1 Year Target Price $86.98
| 4 | Strong Buy |
| 1 | Buy |
| 5 | Hold |
| 1 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 27.82% | Avg. Invested days 76 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/14/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 305.86B USD | Price to earnings Ratio 18.68 | 1Y Target Price 86.98 |
Price to earnings Ratio 18.68 | 1Y Target Price 86.98 | ||
Volume (30-day avg) 12 | Beta 0.22 | 52 Weeks Range 57.00 - 139.45 | Updated Date 07/14/2025 |
52 Weeks Range 57.00 - 139.45 | Updated Date 07/14/2025 | ||
Dividends yield (FY) 2.34% | Basic EPS (TTM) 3.69 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 34.51% | Operating Margin (TTM) 49.68% |
Management Effectiveness
Return on Assets (TTM) 23.29% | Return on Equity (TTM) 88.12% |
Valuation
Trailing PE 18.68 | Forward PE 16.67 | Enterprise Value 317961039568 | Price to Sales(TTM) 1.01 |
Enterprise Value 317961039568 | Price to Sales(TTM) 1.01 | ||
Enterprise Value to Revenue 6.69 | Enterprise Value to EBITDA 13.84 | Shares Outstanding 3368499968 | Shares Floating 3183876215 |
Shares Outstanding 3368499968 | Shares Floating 3183876215 | ||
Percent Insiders 0.01 | Percent Institutions 9.85 |
Upturn AI SWOT
Novo Nordisk A/S
Company Overview
History and Background
Novo Nordisk A/S was founded in 1923 in Denmark. It evolved from Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium, initially focusing on insulin production. Over time, it expanded into diabetes care and biopharmaceuticals, becoming a global leader in these areas.
Core Business Areas
- Diabetes care: Novo Nordisk's primary business segment, focusing on developing and marketing insulin and other diabetes treatments, including GLP-1 receptor agonists and oral anti-diabetic medications.
- Obesity care: Developing and marketing treatments for obesity, including GLP-1 receptor agonists like Wegovy and Saxenda.
- Biopharmaceuticals: Focused on treatments for hemophilia, growth disorders, and other serious chronic diseases.
Leadership and Structure
Novo Nordisk operates under a two-tier management structure: a Board of Directors and an Executive Management team. The CEO leads the Executive Management, overseeing various departments like R&D, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Market Share Data: Ozempic held approximately 47% of the GLP-1 market share in 2023.
- Ozempic (semaglutide): A GLP-1 receptor agonist used to treat type 2 diabetes. It has a significant market share in the GLP-1 market. Estimated revenue in 2023: $12.6 Billion USD. Competitors: Eli Lilly's Trulicity and Mounjaro, AstraZeneca's Bydureon.
- Market Share Data: Wegovyu2019s market share is growing rapidly in the obesity care market and is expected to continue to increase in the coming years. Market share 2023: ~20% of total anti-obesity medication market.
- Number of Users: Approximately 1 Million Users as of 2024 Q1
- Wegovy (semaglutide): A higher-dose version of semaglutide approved for weight management. Wegovy is increasingly prescribed for obesity treatment, though supply constraints are still apparent. Competitors: Eli Lilly's Zepbound, Novo Nordisk's Saxenda.
- Market Share Data: Remains a significant revenue contributor but faces competition from biosimilars. Market share ~15% of total insulin market
- NovoLog/NovoRapid (insulin aspart): A rapid-acting insulin analog used to control blood sugar levels in people with diabetes. Competitors: Eli Lilly's Humalog, Sanofi's Apidra.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly in diabetes and obesity care, is experiencing significant growth driven by increasing prevalence of these conditions and innovation in treatment options.
Positioning
Novo Nordisk is a dominant player in the diabetes care market and is rapidly expanding its presence in the obesity care market. It has a strong R&D pipeline and a reputation for innovation. Its competitive advantage lies in its expertise in metabolic diseases and its established brand recognition.
Total Addressable Market (TAM)
The global diabetes market is estimated at over $100 billion, and the obesity market is expected to exceed $50 billion in the coming years. Novo Nordisk is positioned to capture a significant share of both markets, driven by its innovative products and strong market presence.
Upturn SWOT Analysis
Strengths
- Strong market position in diabetes care
- Innovative product portfolio
- Robust R&D pipeline
- Global brand recognition
- Established distribution network
Weaknesses
- Reliance on a few key products
- Exposure to pricing pressures
- Supply chain vulnerabilities
- Dependence on regulatory approvals
- Competition from biosimilars and generics
Opportunities
- Expansion into new markets (e.g., emerging economies)
- Development of new therapies for related conditions (e.g., cardiovascular disease)
- Strategic acquisitions to diversify product portfolio
- Partnerships with technology companies to enhance digital health solutions
- Growing demand for obesity treatments
Threats
- Increased competition from other pharmaceutical companies
- Patent expirations and generic erosion
- Regulatory changes and healthcare reforms
- Economic downturns and reduced healthcare spending
- Adverse events or safety concerns related to products
Competitors and Market Share
Key Competitors
- LLY
Competitive Landscape
Novo Nordisk and Eli Lilly are the dominant players in the diabetes and obesity care markets. Novo Nordisk has a strong position in diabetes care, while Eli Lilly has gained traction with its Mounjaro and Zepbound products. Competition is intensifying as both companies continue to innovate and expand their product portfolios.
Major Acquisitions
Dicerna Pharmaceuticals
- Year: 2021
- Acquisition Price (USD millions): 3300
- Strategic Rationale: To expand Novo Nordisk's research capabilities in RNA interference (RNAi) therapies.
Growth Trajectory and Initiatives
Historical Growth: Novo Nordisk has experienced strong historical growth, particularly in recent years due to the success of its GLP-1 receptor agonists.
Future Projections: Analysts project continued growth for Novo Nordisk, driven by increasing demand for its diabetes and obesity treatments. Revenue is expected to grow at a double-digit rate in the coming years, with EPS also projected to increase. Expect significant revenue growth from Wegovy
Recent Initiatives: Recent initiatives include expanding manufacturing capacity to meet growing demand, investing in R&D for new therapies, and pursuing strategic partnerships to expand its product portfolio.
Summary
Novo Nordisk is a strong company with a leading position in the diabetes and obesity care markets. Its innovative product portfolio, robust R&D pipeline, and global brand recognition drive its success. However, it faces increasing competition, pricing pressures, and regulatory challenges. Continued investment in R&D and strategic expansion are crucial for sustaining its growth trajectory.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Reports
- Analyst Estimates
- Market Research Reports
Disclaimers:
This analysis is based on publicly available information and analyst estimates. It is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Novo Nordisk A/S
Exchange NYSE | Headquaters - | ||
IPO Launch date 1982-01-04 | President, CEO & Member of Management Board Mr. Lars Fruergaard Jorgensen | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 77406 | Website https://www.novonordisk.com |
Full time employees 77406 | Website https://www.novonordisk.com | ||
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.